Gini Fleming to Aged, 80 and over
This is a "connection" page, showing publications Gini Fleming has written about Aged, 80 and over.
Connection Strength
1.185
-
Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol. 2018 08; 150(2):300-305.
Score: 0.076
-
High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol. 2017 07; 146(1):153-160.
Score: 0.071
-
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 03; 144(3):459-467.
Score: 0.070
-
Treatment of ovarian cancer in the older woman. Gynecol Oncol. 2015 Jan; 136(1):136-42.
Score: 0.060
-
Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Gynecol Oncol. 2014 Mar; 132(3):585-92.
Score: 0.057
-
A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2010 Apr; 117(1):37-40.
Score: 0.043
-
Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2010 Jan; 116(1):15-20.
Score: 0.042
-
Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004 Jun 01; 22(11):2159-66.
Score: 0.029
-
Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial: A Randomized Clinical Trial. JAMA Oncol. 2023 Nov 01; 9(11):1547-1555.
Score: 0.028
-
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial. Gynecol Oncol. 2022 02; 164(2):278-287.
Score: 0.024
-
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 02; 164(2):245-253.
Score: 0.024
-
Phase I trial of concomitant vinorelbine, paclitaxel, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies. Gynecol Oncol. 2001 Aug; 82(2):333-7.
Score: 0.024
-
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
Score: 0.024
-
Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients. Breast Cancer Res. 2021 02 04; 23(1):18.
Score: 0.023
-
Absence of major peripheral neuropathy in a phase II trial of ifosfamide with vinorelbine in patients with ovarian cancer previously treated with platinum and paclitaxel. Am J Clin Oncol. 2001 Feb; 24(1):52-7.
Score: 0.023
-
Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: a Gynecologic Oncology Group Study. Am J Clin Oncol. 2000 Dec; 23(6):609-13.
Score: 0.023
-
Health-related quality of life outcomes for the LEAP study-CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients. Cancer. 2021 01 15; 127(2):300-309.
Score: 0.023
-
A randomized study to prevent lymphedema in women treated for breast cancer: CALGB 70305 (Alliance). Cancer. 2021 01 15; 127(2):291-299.
Score: 0.023
-
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study. Gynecol Oncol. 2020 09; 158(3):640-645.
Score: 0.022
-
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
Score: 0.022
-
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). Clin Cancer Res. 2020 06 01; 26(11):2477-2486.
Score: 0.021
-
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. Clin Cancer Res. 2020 03 01; 26(5):1009-1016.
Score: 0.021
-
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019 12 19; 381(25):2403-2415.
Score: 0.021
-
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. J Clin Oncol. 2019 09 10; 37(26):2317-2328.
Score: 0.021
-
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2019 06 01; 37(16):1380-1390.
Score: 0.020
-
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317.
Score: 0.019
-
Comparison of the incidence of febrile neutropenia in obese and normal weight breast cancer patients receiving myelosuppressive chemotherapy and prophylactic pegfilgrastim. J Oncol Pharm Pract. 2019 Jul; 25(5):1112-1118.
Score: 0.019
-
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
Score: 0.019
-
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecol Oncol. 2018 03; 148(3):507-514.
Score: 0.019
-
Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clin Cancer Res. 2015 Nov 15; 21(22):5092-9.
Score: 0.016
-
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia. Gynecol Oncol. 2015 Jul; 138(1):55-61.
Score: 0.015
-
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. Gynecol Oncol. 2015 May; 137(2):216-22.
Score: 0.015
-
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014 Oct; 15(11):1207-14.
Score: 0.015
-
A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia. Gynecol Oncol. 2014 Aug; 134(2):274-80.
Score: 0.014
-
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2014 Apr 20; 32(12):1210-7.
Score: 0.014
-
ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. Eur J Cancer. 2013 Jan; 49(1):121-31.
Score: 0.013
-
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res. 2012 Sep 01; 18(17):4785-93.
Score: 0.013
-
Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 Dec 29; 365(26):2473-83.
Score: 0.012
-
Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA. 2009 Aug 19; 302(7):774-80.
Score: 0.010
-
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg. 2009 May; 208(5):906-14; discussion 915-6.
Score: 0.010
-
Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues. Clin Cancer Res. 2009 May 01; 15(9):3196-204.
Score: 0.010
-
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 01; 26(7):1119-27.
Score: 0.009
-
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008 Jan 01; 26(1):76-82.
Score: 0.009
-
An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008 Jan; 108(1):3-9.
Score: 0.009
-
The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 Jul; 106(1):16-22.
Score: 0.009
-
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2007 Nov; 60(6):811-9.
Score: 0.009
-
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006 Sep 10; 24(26):4324-32.
Score: 0.008
-
Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study. Br J Clin Pharmacol. 2006 Jul; 62(1):56-70.
Score: 0.008
-
A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancer. Am J Clin Oncol. 2005 Feb; 28(1):65-9.
Score: 0.008
-
Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol. 2003 Jun 15; 21(12):2268-75.
Score: 0.007
-
Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment. Cancer Chemother Pharmacol. 2002 Aug; 50(2):121-6.
Score: 0.006
-
Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2002 Apr 01; 52(5):1330-7.
Score: 0.006
-
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors. Ann Oncol. 2001 Dec; 12(12):1743-7.
Score: 0.006
-
Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. Gynecol Oncol. 2001 Sep; 82(3):456-63.
Score: 0.006
-
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res. 2001 May; 7(5):1214-20.
Score: 0.006
-
Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations. Cancer Chemother Pharmacol. 2000; 45(6):489-94.
Score: 0.005
-
Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1996 Mar; 59(3):349-59.
Score: 0.004